MOv19-BBz CAR T Cells in FRa+ Cancers
NCT: NCT07116057 · RECRUITING
Brief Summary
This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells in patients with FRa+ cancers. This study will be initiated in patients with metastatic or recurrent non-small cell lung cancer (NSCLC) only. Subjects will receive a single dose of MOv19-BBz CAR T cells via intrapleural infusion following lymphodepleting chemotherapy. Subjects without an existing intra-pleural catheter will have a temporary pleural catheter placed for the study. Subjects may initiate treatment with commercial checkpoint inhibitors per routine care beginning at least 28 days after receiving MOv19-BBz CAR T cells.
Frequently Asked Questions
What is MOv19-BBz CAR T Cells in FRa+ Cancers?
MOv19-BBz CAR T Cells in FRa+ Cancers is a clinical trial registered under NCT07116057. Current status: RECRUITING.
What is the status of NCT07116057?
The current status of NCT07116057 (MOv19-BBz CAR T Cells in FRa+ Cancers) is: RECRUITING.
When did MOv19-BBz CAR T Cells in FRa+ Cancers start?
MOv19-BBz CAR T Cells in FRa+ Cancers started on 2025-10-07.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.